A citation-based method for searching scientific literature

K V S Hari Kumar, Altamash Shaikh, Pitambar Prusty. Diabetes Res Clin Pract 2013
Times Cited: 61







List of shared articles



Times cited

The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus.
Kashif M Munir, Stephen N Davis. Expert Opin Pharmacother 2015
11


Role of Noninsulin Therapies in the Treatment of Type 1 Diabetes.
Sara E Lingow, Sandra D Burke, Amie D Brooks, Pat S Rafferty. Diabetes Spectr 2019
0

Non-insulin pharmacological therapies for treating type 1 diabetes.
Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad, Jens Juul Holst. Expert Opin Pharmacother 2018
5

Weight Management in Patients with Type 1 Diabetes and Obesity.
Adham Mottalib, Megan Kasetty, Jessica Y Mar, Taha Elseaidy, Sahar Ashrafzadeh, Osama Hamdy. Curr Diab Rep 2017
29


Use of non-insulin therapies for type 1 diabetes.
Satish K Garg, Aaron W Michels, Viral N Shah. Diabetes Technol Ther 2013
8

Reduced GLP-1 response to a meal is associated with the CTLA4 rs3087243 G/G genotype.
András Zóka, Gábor Barna, Gábor Nyírő, Ágnes Molnár, László Németh, Györgyi Műzes, Anikó Somogyi, Gábor Firneisz. Cent Eur J Immunol 2019
0

Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.
Christian Seerup Frandsen, Thomas Fremming Dejgaard, Sten Madsbad. Lancet Diabetes Endocrinol 2016
46

Adjunctive therapy for glucose control in patients with type 1 diabetes.
Kira Harris, Cassie Boland, Lisa Meade, Dawn Battise. Diabetes Metab Syndr Obes 2018
9

Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Thomas Fremming Dejgaard, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Søren Urhammer, Ulrik Pedersen-Bjergaard, Tonny Jensen, Andreas Kryger Jensen, Jens Juul Holst, Lise Tarnow,[...]. Lancet Diabetes Endocrinol 2016
71

GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?
Djordje S Popovic, Edita Stokic, Stevan L Popovic. Curr Pharm Des 2015
4

Evolving Pharmacotherapeutic Strategies for Type 1 Diabetes Mellitus.
Samie Sabet, Michelle E Condren, Angela F Boston, Lauren C Doak, Laura J Chalmers. J Pediatr Pharmacol Ther 2018
1


Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis.
Wen Wang, Yun Gao, Dawei Chen, Chun Wang, Xiaobing Feng, Xingwu Ran. Diabetes Res Clin Pract 2017
6


Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.
Thomas Fremming Dejgaard, Filip Krag Knop, Lise Tarnow, Christian Seerup Frandsen, Tanja Stenbæk Hansen, Thomas Almdal, Jens Juul Holst, Sten Madsbad, Henrik Ullits Andersen. BMJ Open 2015
9


Adjunct therapies in treatment of type 1 diabetes.
Itivrita Goyal, Alamgir Sattar, Megan Johnson, Paresh Dandona. J Diabetes 2020
3

Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
Justinne Guyton, Michelle Jeon, Amie Brooks. Am J Health Syst Pharm 2019
0

GLP-1 Agonists in Type 1 Diabetes Mellitus.
Kristin M Janzen, Taylor D Steuber, Sarah A Nisly. Ann Pharmacother 2016
17

Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Christian S Frandsen, Thomas F Dejgaard, Jens J Holst, Henrik U Andersen, Birger Thorsteinsson, Sten Madsbad. Diabetes Care 2015
50